# Enhanced Epidermal Antigen Specific Immunotherapy Trial -1

> **NCT02837094** · PHASE1 · COMPLETED · sponsor: **Cardiff University** · enrollment: 6 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** C19-A3 GNP

## Key facts

- **NCT ID:** NCT02837094
- **Lead sponsor:** Cardiff University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-29
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02837094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02837094, "Enhanced Epidermal Antigen Specific Immunotherapy Trial -1". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02837094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*